Business Environment

September 16, 2025 | Business Environment

Briya Provides No-Cost AI Tools to Advance Medical & Epidemiological Research

Briya, the health AI technology company redefining healthcare research, announced that following the launch of Briya AIRE™, it will provide free access to the first clinical-grade AI platform to accelerate medical and epidemiological research for select academic medical centers and research institutions facing financial and economic strain. This initiative comes at a critical moment for the medical research field. Budget cuts, hiring freezes, and laboratory closures have threatened to slow progress at U.S. academic medical centers and biopharma research institutions. "As healthcare research programs face mounting pressure, we believe it's our responsibility to help institutions preserve vital research capacity," said David Lazerson, Co-founder and CEO of Briya. "We must not allow a lack of funding or resources to hinder life-saving research. By turning months into minutes, Briya AIRE allows organizations to accelerate discovery and innovation that directly impacts patient outcomes, even when resources are stretched." Briya AIRE acts as a virtual epidemiologist and data analyst, enabling researchers without coding expertise to design patient cohorts, test hypotheses, refine study criteria and uncover hidden patterns. By guiding users through each stage of methodology - from structuring research questions to shaping protocols and validating study design and endpoints - it strengthens the rigor and reliability of clinical research. AIRE translates everyday language into precise medical terms, integrating data from EHRs, research databases, and clinical notes to streamline study design and accelerate discoveries. This allows institutions to streamline methodology, reduce manual preparation and accelerate discovery. Built on Briya's secure infrastructure, it helps institutions drive innovation in drug development and patient care while ensuring regulatory compliance.

September 16, 2025 | Business Environment

Emporia Research Scales Healthcare Research Recruitment Network

Emporia Research, a leader in B2B research participant recruitment, announced the expansion of its capabilities into healthcare research. The company will now support clients in recruiting physicians, healthcare executives and clinical staff, three critical audiences that have historically been underserved in research recruitment. With access to over 10 million healthcare professionals across therapeutic specializations and niche subgroups, Emporia Research is uniquely positioned to deliver precise, compliant and cost-effective recruitment solutions. "We see healthcare as a huge opportunity," said Michael Hess, Co-Founder and CEO of Emporia Research. "For too long, healthcare research recruitment has been underserved and fragmented, with clients consistently asking for more. By bringing the same programmatic engine and rigorous fraud prevention we've used in B2B research, we can deliver a new level of value to the healthcare ecosystem." Emporia's programmatic recruitment engine offers a new path forward: competitive pricing combined with industry-best fraud detection rates, the same benchmark the company has already achieved in B2B research. "We have invested heavily in building out our healthcare asset," said Jake Roeland, Co-Founder and CTO of Emporia Research. "While we know there is still a long way to go, we have focused on developing the ability to deeply profile healthcare professionals in ways that matter for research. Our approach is built on a foundation of trust in who the person is, supported by LinkedIn verification and relevant credentialing. This gives our clients confidence that they are hearing directly from the right voices in healthcare."

September 15, 2025 | Business Environment

IQVIA Launches AI-Powered Clinical Trial Financial Suite

IQVIA, a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced the launch of its Clinical Trial Financial Suite (CTFS), an AI-enabled platform orchestrating all financial aspects of clinical trials. CTFS is designed to eliminate inefficiencies created by siloed systems and fragmented processes. In contrast to other industry offerings, CTFS unifies budgeting, contracting, forecasting and payment workflows with shared data and end-to-end processes. The suite’s first module, CTFS Site Payments, brings end-to-end automation to one of the most complex trial processes. By leveraging agentic AI to set up budgets, process invoices and identify anomalies, the module frees up financial teams from repetitive manual tasks to focus their attention more productively. IQVIA’s technology and operations experts behind CTFS have supported site and participant payments across more than 200 geographies. The solution uses advanced technology to deliver enterprise-grade scalability and security, while deploying AI to drive efficiency and acceleration to the most manual and burdensome processes. Projected customer outcomes include up to 50% reduction in processing time. “With CTFS, we are building the financial backbone for modern clinical trials — unified, globally scalable and powered by agentic AI,” said Bernd Haas, Senior Vice President, Digital Products & Solutions at IQVIA. “From protocol to payments, we’re connecting and simplifying financial processes into a seamless, transparent experience for sponsors, CROs and study sites alike.”

September 12, 2025 | Business Environment

Novo Nordisk to Cut 9,000 Jobs in Global Transformation Drive

Novo Nordisk announced a company-wide transformation to simplify its organisation, improve the speed of decision-making, and reallocate resources towards the company’s growth opportunities in diabetes and obesity. As part of the transformation, Novo Nordisk intends to reduce the global workforce by approximately 9,000 of the 78,400 positions in the company, with around 5,000 reductions expected in Denmark. The transformation reflects the Company’s commitment to meet rising global demand while also competing in a more dynamic and consumer-driven obesity market, as evidenced by the recent slowdown in growth. Over the past years, Novo Nordisk’s rapid scaling has increased organisational complexity and costs. The transformation aims at addressing that complexity, so Novo Nordisk can invest more behind its science, commercial capabilities and manufacturing ramp-up – aiming to reach the millions of people who remain untreated. Mike Doustdar, Novo Nordisk president and CEO, said: “As the global leader in obesity and diabetes, Novo Nordisk delivers life-changing products for patients worldwide. But our markets are evolving, particularly in obesity, as it has become more competitive and consumer-driven. Our company must evolve as well. This means instilling an increased performance-based culture, deploying our resources ever more effectively, and prioritising investment where it will have the most impact – behind our leading therapy areas.”

September 12, 2025 | Business Environment

Trinity Capital Invests $26M to Advance Workplace Mental Health with Unmind

Trinity Capital Inc. , a leading alternative asset manager, today announced the commitment of $26 million in growth capital to Unmind, the workplace mental health platform delivering complete care in one solution, powered by AI. Unmind combines human expertise, digital innovation, and proven science so every employee can access the right support – from proactive and preventative AI guidance to therapy, coaching, crisis care, 24/7 programs, and wellbeing progress tracking. With tailored solutions for individuals, leaders, and organizations, Unmind helps build high-performing teams while driving productivity and growth for enterprises. "In today's world, prioritizing mental health is vital, not just for individuals, but for the way we live and work together," said Craig Fox, Managing Director of Tech Lending at Trinity Capital. "Unmind is transforming how people and businesses thrive, and we are proud to partner with a team so deeply committed to bringing wellbeing into the workplace." This new debt financing will help scale Unmind's operations, further develop its proprietary AI agent "Nova," attract talent, and invest in innovation. Trinity Capital's $26 million funding, along with Unmind's recent Series C and prior financings, brings the company's total capital raised since inception to more than $100 million. Dr. Nick Taylor, CEO and Co-Founder of Unmind, commented: "Workplace mental health has reached a turning point. Organizations now recognize they need solutions that support their people at every level – from proactive tools for individuals, to mental health training for leaders, to insights that shape whole-organization strategy. With Nova, our mental health agent at the center of the platform, we can guide every person to the right level of care while enabling businesses to build resilient, high-performing teams. Trinity's support accelerates our work to deliver complete mental health care that drives both human and business potential."

September 11, 2025 | Business Environment

Springbuk Acquisition Expands Truven’s Reach in Employer Health & Benefits Analytics

Truven by Merative, a leading portfolio of healthcare analytics and real-world data solutions, has acquired Springbuk, a leading health intelligence platform for employers and their advisors. This transaction adds more than 7,500 small- and mid-market employers to the Truven customer base that already includes more than 40 percent of Fortune 100 employers and 7 of the top 10 U.S. health plans by enrollment. "Truven and Springbuk are a powerful combination that can scale to meet a wide range of employer needs," said Marcy Tatsch, executive vice president and general manager, Truven. "From small businesses looking for streamlined options to the nation's largest employers and health plans with complex analytics and care management needs, Truven's portfolio can quickly get them the actionable insights they require." Truven and Springbuk bring together several proven solutions that will continue to serve the employer market. "Our team remains relentlessly focused on tackling the issues of rising healthcare costs, benefits program effectiveness, and improving the health of employees," said Joy Powell, chief executive officer of Springbuk. "By joining Truven, Springbuk will scale and help more employers leverage the benefits of Truven's one-of-a-kind MarketScan data, industry benchmarks and advanced analytics."

September 10, 2025 | Business Environment

Havas Health Expands into Taiwan, Boosting APAC Presence

Havas Health Network announced the official launch of Havas Health in Taiwan, further expanding the network's presence across the broader Asia-Pacific region. Operating within the Havas Taiwan Village, the new healthcare-focused agency reflects the network's commitment to delivering world-class, data-driven healthcare communications in key global markets. Havas Health in Taiwan is fully integrated into the Havas Taiwan Village model, a unified structure that connects creative, media, and health capabilities under one collaborative framework, enabling seamless, cross-disciplinary support for health and well-being clients and strategic consistency across all offerings. "Taiwan represents a tremendous opportunity to elevate and advance healthcare marketing in a region rich in innovation and poised for accelerated growth," said Charles Houdoux, Global Chief Client Officer and CEO of Havas Health APAC & LATAM. "This launch reflects our commitment to meeting the needs of both global and regional clients through culturally relevant, innovation-driven work. Backed by a global network of more than 6,000 experts, the Taiwan team is uniquely positioned to support and elevate healthcare marketing across Asia." The new office builds on the success of other Havas Villages across the APAC region and aims to carry that momentum into Taiwan's rapidly expanding healthcare sector.

September 04, 2025 | Business Environment

BioFactura Launches Capitol Biologics CDMO for Emerging Biotech

BioFactura, Inc., a clinical‑stage biopharmaceutical company specializing in high‑value biosimilars and critical biodefense medical countermeasures, announced the formation of Capitol Biologics, a new Contract Development and Manufacturing Organization (CDMO) division dedicated to supporting the process development, early‑phase clinical manufacturing, and analytical needs of emerging biotechnology companies and U.S. government agencies. Strategically located in the BioHealth Capital Region, Capitol Biologics combines technical excellence, regulatory expertise, and personalized collaboration to advance innovative biologics from lab bench to first‑in‑human studies. Building on BioFactura's two decades of expertise in biologics development, Capitol Biologics will deliver full‑service, phase‑appropriate manufacturing solutions for monoclonal antibodies, recombinant proteins, and other complex biologics. The division combines advanced cell line development, upstream and downstream process optimization, GMP manufacturing, and extensive analytical and quality control capabilities under a unified quality management system aligned to global regulatory standards (FDA, EMA, ICH). President and CEO Darryl Sampey stated, "Transforming the biopharma development engine that BioFactura has built over the past 20 years into a pure-play service organization provides an incomparable value to early-stage ventures and initiatives. The depth of experience, know-how and capability that we have gained saves our clients both time and money that are in many cases existential to their survival and success." "Capitol Biologics represents the next evolution of BioFactura's mission," said Dr. Jeffrey Hausfeld, M.D., M.B.A., F.A.C.S., Chairman of the Board and Chief Medical Officer of BioFactura. "We are combining our proven technical excellence in biologics development with a personalized, collaborative service model for our clients. Our goal is to help innovators advance their therapies to clinical reality faster, more efficiently, and with the highest quality standards. This new division allows us to share our expertise, infrastructure, and passion for science with the broader biotech community at a critical stage of their growth."

September 03, 2025 | Business Environment

New ATD Study Highlights Gaps in Manager Training Despite High Demand

Most organizations currently offer a manager development program with the goal of improving manager performance, but more than 90 percent of organizations say a lack of time to participate in training is a challenge, according to new ATD research. According to Manager Development: Driving Organizational Success, survey respondents indicated that it is very important that managers be proficient in communication, providing feedback, and performance management. Providing feedback was a significant area of focus in manager development training. Of the 53 percent of survey respondents who indicated that their organizations offer post-training activities to managers, the most common form offered was access to a resource library on manager skills. This library might include articles, job aids, videos, and other tools to teach and reinforce skills. Other key findings in the report include: The top goals of manager development programs are to improve performance by both the manager and the manager's direct reports. Organizations use various delivery methods and instructional techniques when training managers. High-performing organizations are especially likely to use pre- and post-training activities and bite-sized learning in manager training. Sixty-two percent of organizations use coaching or mentoring when training managers. ATD surveyed 409 talent development professionals across a variety of industries to learn more about the goals and challenges of manager development, the topics and methods used in training managers, and how organizations continue to support manager development.

August 26, 2025 | Business Environment

South University’s Clinical Mental Health Counseling Program Earns CACREP Accreditation

South University (SU) is pleased to announce that its Clinical Mental Health Counseling (CMHC) Master of Arts program at the West Palm Beach campus has been granted Accredited Status by the Council for Accreditation of Counseling and Related Educational Programs (CACREP). Dr. Bridget Glass, Program Director and Assistant Professor of Clinical Mental Health Counseling at SU, West Palm Beach, said, "Our program's delivery formats—blending in-person, virtual, and asynchronous learning—allow us to meet diverse student needs while maintaining the highest academic and professional standards." The CHMC curriculum, while flexible, includes required in-person components across clinical, practicum, and/or externship experiences designed to prepare graduates for professional practice and licensure and provide a path for graduates to satisfy national certification and state licensure requirements to work in the counseling field. Requirements vary by state, and South University cannot guarantee passage of licensure examinations, certification, employment, or salary outcomes. For additional details, students should consult the State Professional Licensure Determination and National Certification/Licensure section of the South University catalog. "This accreditation affirms the strength of our program and its alignment with national standards," said Dr. Jessica Masoner, Dean of the South University College of Arts and Sciences. "We are committed to supporting our students' development as they prepare for impactful careers in counseling and to advancing the university's mission of delivering quality education in behavioral health disciplines."

Page 1 of 41

Featured Recruiters